USPTO issues patent for Lixte's LB-100 to treat cancer

[News]

John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announces that the United States Patent and Trademark Office awarded a patent on its lead compound, LB-100, as well as a number of structurally related compounds, which has shown promising anti-cancer activity.

More... (http://www.news-medical.net/news/20110923/USPTO-issues-patent-for-Lixtes-LB-100-to-treat-cancer.aspx)